LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.59 0.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

79.25

Max

82.67

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+16.96% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.1B

14B

Ankstesnė atidarymo kaina

81.02

Ankstesnė uždarymo kaina

81.59

Naujienos nuotaikos

By Acuity

58%

42%

290 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-02 23:41; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026-03-02 23:37; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026-03-02 23:26; UTC

Svarbiausios naujienos

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026-03-02 22:41; UTC

Rinkos pokalbiai

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026-03-02 22:32; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 22:32; UTC

Rinkos pokalbiai

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026-03-02 22:21; UTC

Rinkos pokalbiai

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026-03-02 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-02 22:11; UTC

Rinkos pokalbiai

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026-03-02 22:10; UTC

Įsigijimai, susijungimai, perėmimai

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026-03-02 22:06; UTC

Rinkos pokalbiai

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026-03-02 22:00; UTC

Rinkos pokalbiai
Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 22:00; UTC

Rinkos pokalbiai
Uždarbis

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-02 21:35; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026-03-02 21:34; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026-03-02 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026-03-02 21:17; UTC

Svarbiausios naujienos

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026-03-02 20:44; UTC

Uždarbis

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026-03-02 20:43; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2026-03-02 20:28; UTC

Uždarbis

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026-03-02 20:25; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026-03-02 20:24; UTC

Uždarbis

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026-03-02 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026-03-02 20:12; UTC

Svarbiausios naujienos

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026-03-02 20:08; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 20:08; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026-03-02 20:05; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

16.96% į viršų

12 mėnesių prognozė

Vidutinis 95.86 USD  16.96%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

12

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

290 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat